Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 15.5% in June

Achilles Therapeutics plc (NASDAQ:ACHL) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 23,500 shares, a decline of 15.5% from the May 31st total of 27,800 shares. Based on an average trading volume of 194,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Achilles Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP bought a new position in shares of Achilles Therapeutics in the fourth quarter worth about $96,000. Acadian Asset Management LLC bought a new position in shares of Achilles Therapeutics in the first quarter worth about $350,000. StemPoint Capital LP bought a new position in shares of Achilles Therapeutics in the first quarter worth about $1,732,000. Ikarian Capital LLC bought a new position in shares of Achilles Therapeutics in the first quarter worth about $1,804,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of Achilles Therapeutics in the fourth quarter worth about $2,127,000. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Price Performance

ACHL opened at $0.82 on Friday. Achilles Therapeutics has a twelve month low of $0.74 and a twelve month high of $1.76. The company has a 50-day simple moving average of $0.87 and a 200 day simple moving average of $0.97. The stock has a market capitalization of $33.49 million, a price-to-earnings ratio of -0.51 and a beta of 1.35.

Achilles Therapeutics (NASDAQ:ACHL) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.16. Sell-side analysts anticipate that Achilles Therapeutics will post -1.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ACHL. Chardan Capital reduced their target price on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, April 5th. Piper Sandler reissued a “neutral” rating and issued a $2.00 target price (down previously from $8.00) on shares of Achilles Therapeutics in a research report on Friday, April 5th.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.